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The Cost of Living: 
The Impact of the Increasing Cost of Pharmaceutical Drugs on Public Health 
 
I. Introduction 
The rise in pharmaceutical prices has become a growing public health concern, particularly 
in a society where approximately 50% of all Americans take at least one prescription drug.1  From 
2008 through 2015, the price of brand name drugs increased by 164%.2  The twenty most 
commonly prescribed brand name drugs offered under Medicare’s Part D program has increased 
approximately 12% every year.3  The Center for Medicare and Medicaid Services (“CMS”) 
predicts an average increase of 6.3% per year for prescription drugs.4   
The rising pharmaceutical costs impacts many different constituents.  Most directly, 
individual purchasers bear the greatest burden and many must choose between the cost of medicine 
and foregoing treatment.5  Insurance companies also face increased costs of insuring individuals.  
Government budgets, at the federal and state levels, swell to sustain funding for Medicare and 
Medicaid coverage.  Conversely, pharmaceutical companies stress a need to generate suitable 
profit margins and funds for additional research and development.  Without proper remediation, 
pharmaceutical costs may have a detrimental effect on the nation’s economy and public health.  
                                                 
1 CENTER FOR DISEASE CONTROL AND PREVENTION, PRESCRIPTION DRUG USE IN THE PAST 30 DAYS BY SEX, RACE, 
AND HISPANIC ORIGIN, AND AGE: UNITED STATES, SELECTED YEARS 1988-1994 THROUGH 2011-2014 (2017), 
https://www.cdc.gov/nchs/data/hus/2017/079.pdf. 
2 GLEN STETTIN AND ROCHELLE HENDERSON, EXPRESS SCRIPTS 2015 DRUG TREND REPORT 8 (2016). 
3 UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE, 
115TH CONG., MANUFACTURED CRISIS: HOW DEVASTATING DRUG PRICE INCREASES ARE HARMING AMERICA’S 
SENIORS 3 (2018). 
4 CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2016-2025 
(2017). 
5 Timothy Kelley, When the Cost of Medications Keeps Patients from Taking Them, MANAGED CARE (June 3, 
2018), https://www.managedcaremag.com/archives/2018/6/when-cost-medications-keeps-patients-taking-them. 
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This paper will discuss (i) the causes of these increasing costs, (ii) the impacted parties, (iii) 
measures taken and proposed by federal and state governments, (iv) the challenges with the taken 
and proposed measures, and (v) lastly, propose four strategies to combat rising pharmaceutical 
costs.    
II. Background 
A. What are Pharmaceutical Drugs? 
The purchase of prescription and over-the-counter drugs determines the success of the 
pharmaceutical industry.  Prescription drugs can be separated into two primary categories: (1) 
brand-name drugs; and (2) generic drugs.  Each play an integral role in the pharmaceutical industry 
and contribute to price fluctuations within the market. 
The Food and Drug Administration (FDA) defines brand-name drugs as “a drug marketed 
under a proprietary, trademark-protected name.”6  Brand-name drugs are researched, developed 
and tested by pharmaceutical companies, large and small.  At some point during the development 
phase, companies then file for patent protection.7  An approved patent protects the drug formula 
from being copied or marketed, affording a company with years of protection against competition.  
In addition to patent protection, the FDA can grant brand-name drugs “exclusivity;” thereby, 
allowing for an additional period of time when a brand-name drug is protected from generic drug 
competition. 8  As such, brand-name drugs typically charge a higher price.     
A generic drug is “the same as a brand-name drug in dosage, safety, strength, how it is 
taken, quality, performance and intended use.”9  The primary difference is that the generics do not 
                                                 
6 Food and Drug Administration, Glossary of Terms, FOOD AND DRUG ADMINISTRATION (Nov. 14, 2017), 
https://www.fda.gov/drugs/informationondrugs/ucm079436.htm#B. 
7 DEPRESSION AND BIPOLAR SUPPORT ALL., GENERIC AND BRAND NAME DRUGS: UNDERSTANDING THE BASICS 3 
(2007). 
8 FOOD AND DRUG ADMINISTRATION, EXCLUSIVITY AND GENERIC DRUGS: WHAT DOES IT MEAN? (2018). 
9 Food and Drug Administration, supra note 6. 
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have a patent and, oftentimes, do not operate under a brand name.  As such, generic drugs can be 
expected to have equal effect and no difference when substituted for the brand-name product.10  
Moreover, Generic drugs are typically cheaper than their brand-name counterparts.  
B. Pharmaceutical Pricing Trends 
Pharmaceutical pricing has remained a growing public health concern since the early 1990s 
as U.S. drug spending grew between 11 and 17% per year.  As more complex and expensive drugs 
were developed, insurance plans utilized formularies and co-payments to keep drug costs low.11  
Additionally, drug manufacturers began offering rebates and discounts in order to decrease the 
number of drugs excluded from coverage.12  As prices rose, private insurers took other means to 
quell the increases in net drug prices by closing formularies to manage drug spending and 
negotiating higher rebates and discounts from drug manufacturers.13  However, the narrative 
remains the same approximately thirty years later; pharmaceutical prices continue to rise.  As 
previously stated, from 2008 through 2015, the price of brand-name drugs increased by 164%14; 
with brand price inflation nearly doubling between 2011 and 2015.15  In the U.S., cancer drugs 
routinely cost $10,000 per month.16  Twenty of the most commonly prescribed brand-name drugs 
offered under Medicare’s Part D program increased approximately 12% annually from 2012 
through 2017.17 
As pharmaceutical prices increased, so did prescription drug spending.  Between 2006 and 
                                                 
10 Id. 
11 THE UNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICES, AMERICAN PATIENTS FIRST: THE TRUMP 
ADMINISTRATION BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT-OF-POCKET COSTS 13 (2018). 
12 Id. 
13 Id.  
14 GLEN STETTIN, ROCHELLE HENDERSON, supra note 2 at 8. 
15 Id. 
16 Robert Langreth, Drug Prices, BLOOMBERG, May 11, 2018, https://www.bloomberg.com/quicktake/drug-prices.  
17 UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE, 
115TH CONG., MANUFACTURED CRISIS: HOW DEVASTATING DRUG PRICE INCREASES ARE HARMING AMERICA’S 
SENIORS 2 (2018). 
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2015, retail prescription drug spending increased by an average of approximately 4.8% annually.18  
For much of this time, the use of generic drugs limited price increases.19  However, drug spending 
in 2014 and 2015 grew by an astounding 12.4% and 9% respectively.20  These figures are even 
more overwhelming when compared to the average rate of inflation, between 2006 and 2016, of 
1.8%.21 
Americans spend more on drugs than the rest of the world.  On average, Americans spend 
$1,200 per year on pharmaceuticals.22  Switzerland, the second highest, spends $1,080.23  Canada 
spends $860; Germany spends $777; France spends $663; and the United Kingdom spends $476.24  
Increased spending is not a distinguishable difference.  U.S. prices for the world’s top-twenty 
medicines are, on average, three times higher than in Britain.25  For example, Roche Holding AG’s 
Herceptin breast cancer drug, after rebates of roughly 15%, still cost approximately 85% more in 
the U.S. than in other high-income countries.26  After an estimated discount of 60%, AstraZeneca 
charges twice as much in the U.S. for Crestor compared to Germany.  A 2013 study that found that 
20% of adults in the U.S. failed to complete a prescribed course of medicine because of cost.27  
Comparatively, Germany, Canada, and Australia had a rate of 10%.28  
                                                 
18 UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE, 
Supra note 3, at 3. 
19 Robert Langreth, Drug Prices, BLOOMBERG, May 11, 2018, https://www.bloomberg.com/quicktake/drug-prices. 
20 UNITED STATES SENATE HOMELAND SECURITY & GOVERNMENTAL AFFAIRS COMMITTEE, MINORITY OFFICE, 
Supra note 3, at 3. 
21 Kimberly Amadeo, U.S. Inflation Rate from 1929 to 2020, THE BALANCE (July 6, 2018), 
https://www.thebalance.com/u-s-inflation-rate-history-by-year-and-forecast-3306093 
22 Organisation of Economic Co-Operation and Development, Pharmaceutical Spending, OECD (Nov. 8, 2018), 
https://data.oecd.org/healthres/pharmaceutical-spending.htm. 
23 Id. 
24 Id. 
25 Ben Hirschler, Transatlantic Divide: How U.S. pays three times more for drugs, REUTERS (Oct. 12, 2015), 
https://www.reuters.com/article/us-pharmaceuticals-usa-comparison/exclusive-transatlantic-divide-how-u-s-pays-
three-times-more-for-drugs-idUSKCN0S61KU20151012. 
26 Robert Langreth, Blacki Migliozzi, Ketaki Gokhale, The U.S. Pays a Lot More for Top Drugs Than Other 
Countries, BLOOMBERG (Dec. 18, 2015), https://www.bloomberg.com/graphics/2015-drug-prices/. 
27 Robert Langreth, Drug Prices, BLOOMBERG (May 11, 2018), https://www.bloomberg.com/quicktake/drug-prices. 
28 Id.  
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Under the current law and policy initiatives, the Centers for Medicare and Medicaid 
Services (“CMS”) projects national health spending to grow at an average rate of 5.5% per year 
from 2017 through 202629; totaling $5.7 trillion by 2026.30  Within health spending, CMS 
anticipates that prescription drug costs will see the fastest annual growth among health care 
expenditures over the next decade.31  Its February 2018 report, CMS projected a 2.3% acceleration 
in prescription drug prices: from 2.1% in 2017 to 4.4% in 2018.32  This acceleration “reflects the 
expectation that brand-name drug prices will more strongly influence growth in that year because 
the dollar value of drugs losing patents in 2018 is smaller than in prior years.”33  Though drug 
price growth is lower than previous years, CMS predicts that through 2025 pharmaceutical prices 
will rise an average of 6.3% per year due to a greater use of specialty drugs such as those used for 
genetic disorders and cancer.34   
III. Causes of the Increasing Costs 
The cost of pharmaceutical drugs can be attributable to various factors including regulatory 
advantages (patent and exclusivity durations), commercially creative approaches deployed by 
manufacturers (discounts and rebates, “gag” clauses) and limitations on government’s ability to 
intervene (absence of direct price regulation, and inability for Medicare to negotiate directly with 
manufacturers).   
Patent and “Exclusivity” periods give a manufacturer a non-competitive marketplace to 
sell theirs drugs.  A U.S. patent precludes another party, including generic drug makers, give a 
                                                 
29 CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2016-2025 
(2017). 
30 Id. 
31 CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2017-2026 
(2018). 
32 Id. 
33 Id. 
34 CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURE PROJECTIONS 2016-2025 
(2017). 
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patent holder the exclusive right to exclude others from making, using, importing, and selling the 
patented innovation for a limited period of time, typically twenty years.35  Manufacturers argue 
that the protections and the related costs are necessary to recover years of research and 
development costs.  In certain cases, the FDA may grant a drug “exclusivity” for a period of time 
to protect it from generic drug competition36 and promote a balance between innovation and 
generic drug competition.37  Drugs may be granted exclusivity for a variety of reasons.  Drugs that 
feature a new chemical entity are given five-year exclusivity.38  Orphan drugs, defined as drugs 
for a disease or condition affecting fewer than 200,000 people, are granted seven-year 
exclusivity.39  A brand-name drug may receive three-year exclusivity if the drug’s active ingredient 
can be delivered in a new way or be used to treat a different disease or condition.40  Exclusivity 
and patent protections provide brand-name drugs a monopoly allowing them to charge higher rates.  
Upon the expiration of patent and exclusivity protection, the cost of the brand-name drug 
decreases; though typically not to the level of its generic counterparts due to recognition.   
While “generics” cannot be granted patent protection, “the first generic drug applicant to 
submit a substantially complete generic application” that challenges a brand-name drug’s patents 
and satisfies regulatory and legal requirements may be eligible for a 180-day exclusivity period.41  
The 180-day period begins from the first occurrence of either the date the sponsor begins 
commercial marketing of the generic drug product or the date of a court decision holding “the 
patent is invalid, unenforceable, or not infringed.”42  Prior to reaching the market, the generic drug 
                                                 
35 35 U.S.C. §1 et. Seq. (1999). 
36 FOOD AND DRUG ADMINISTRATION, EXCLUSIVITY AND GENERIC DRUGS: WHAT DOES IT MEAN? (2018). 
37 Id. 
38 Id.  
39 Id.  
40 Id. 
41 FOOD AND DRUG ADMINISTRATION, EXCLUSIVITY AND GENERIC DRUGS: WHAT DOES IT MEAN? (2018). 
42 FOOD AND DRUG ADMINISTRATION, PATENTS AND EXCLUSIVITY 3 (FDA/CDER SBIA Chronicles, 2015). 
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must be  approved by the FDA.  As such, the generic drug undergoes rigorous testing to ensure its 
“substitutability” to its brand name counterpart.43  Testing must reveal that the generic drug 
contains identical amounts of the same ingredient(s) as the brand-name product.44  Since the 
chemical makeup is identical, generic drugs can be expected to have equal effect and no difference 
when substituted for the brand-name product.45  Generic drugs are typically cheaper than their 
brand-name counterparts costing on average between 80 to 85% less than brand name drugs.46  In 
2010, the use of generic drugs saved consumers $158 billion.47 
Discounts and rebates are used by pharmaceutical manufacturers as a means to provide the 
purchaser a price reduction without impacting the manufacturer’s profit margin.  In both scenarios 
the manufacturer increases the list-price of the drug, with the understanding that price reductions 
will be provided to entice purchasers and pharmacists.  A discount is a reduction in the amount 
that a seller charges a buyer48, typically a pharmacy, with the intent that the pharmacy will promote 
that manufacturer’s product rather than a competitor’s.49  Discounts are provided in order to 
increase the use of higher priced drugs. 
Rebates also operate as a reduction in price with the intent of increasing sales.  Unlike 
discounts which are paid upon purchase, a buyer receives the benefit in the future.  Such is 
necessary because rebates are based upon product sales.50   While rebates for generic drugs are 
paid to a pharmacy or wholesaler, rebates for patented, brand-name products are paid to the 
pharmacy benefit managers (PBMs).  PBMs operate as a healthcare intermediary and include 
                                                 
43 Food and Drug Administration, supra note 6. 
44 Id. 
45 Id. 
46 FOOD AND DRUG ADMINISTRATION, FACTS ABOUT GENERIC DRUGS 2 (2009). 
47 Id.  
48 Norman V. Carroll, Discounts, Rebates, and Kickbacks, PHARMACY BUSINESS AND ECONOMICS BLOG (June 17, 
2015), https://wp.vcu.edu/nvcarroll/2015/06/17/discounts-rebates-and-kickbacks/. 
49 Id. 
50 Id. 
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companies such as CVS Health, Express Scripts, US Scripts, and Humana.  PBMs represent health 
insurers, union health plans, and government purchasers in the selection, purchase and distribution 
of pharmaceuticals.51  Since PBMs influence which drug products are the most frequently used, 
rebates are paid so a PBM will grant the drug exclusive or preferred status.  Exclusive status 
guarantees that the drug is the only one available on the formulary.52  Preferred status provides 
that that drug’s copay is less than the copay for similar products.53  Rebates remain extremely 
costly for pharmaceutical manufacturers.  In 2017, rebates paid by the thirteen largest 
manufacturers totaled $150 billion, double those paid in 2011.54  Because health plans, PBMs and 
wholesalers receive higher rebates and fees when list prices increase, there is little incentive to 
control list prices.55 
“Gag clauses” are commercial contracts between a pharmacy and a PBM that remain 
largely invisible to consumers purchasers.56  These arrangements restrict pharmacists from 
informing consumers about “available alternative pricing, including paying out-of-pocket, 
generics or brand-name products that may be less costly, or those which may be comparatively 
more suitable for a patient” than the prescribed drug.57   
Government’s inability to impact drug pricing also significantly contributes to the problem.  
Unlike Europe, the U.S. does not directly regulate pharmaceutical prices.  As such, pharmaceutical 
companies are able to set prices according to what they or the market dictates leading to U.S. 
                                                 
51 Cole Werble, Pharmacy Benefit Managers, HEALTHAFFAIRS (Sept. 14, 2017), 
https://www.healthaffairs.org/do/10.1377/hpb20171409.000178/full/.  
52 Carroll, supra note 48. 
53 Id. 
54 David Belk, Paul Belk, The Pharmaceutical Industry, True Cost of Healthcare Blog (2018), 
http://truecostofhealthcare.org/the_pharmaceutical_industry/. 
55 THE UNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICES, AMERICAN PATIENTS FIRST: THE TRUMP 
ADMINISTRATION BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT-OF-POCKET COSTS 17 (2018). 
56 Id. 
57 Richard Cauchi, Recent Approaches and Innovations in State Prescription Drug Laws, NATIONAL CONFERENCE 
OF STATE LEGISLATURES (Oct. 1, 2018), http://www.ncsl.org/research/health/rx-costs.aspx#Rx_transparency. 
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pharmaceutical prices being are among the highest in the world.   From 2011 through 2017, the 
thirteen largest pharmaceutical companies received 45% of its global revenue from the U.S.58  The 
remaining 55% came from all other countries combined.59   
Comparatively, European governments directly regulate prices using different 
formulations.  The most widely accepted formulation is “External Price Referencing” (“EPR”), 
where is used in twenty-nine countries in the European Union as well as Iceland, Norway, 
Switzerland, and Turkey.60  EPR is defined by the European Commission, the governing body of 
the European Union, “as the practice of using the price(s) of a medicine in one or several countries 
in order to derive a benchmark or reference price for the purposes of setting or negotiating the 
price of a medicine in a given country.”61  The United Kingdom ‘s National Health Service 
employs a “sufficient value for money” formula and has  refused to pay for certain cancer drugs, 
widely used in the U.S.62  As a result, pharmaceutical manufacturers are constricted when setting 
prices in European markets; leading manufacturers to charge higher fees in the U.S. market.    
More limiting is Medicare’s inability to negotiate drug prices with pharmaceutical 
companies.  Under the Social Security Act, Medicare “may not interfere with the negotiations 
between drug manufacturers, pharmacies and PDP sponsors, and may not require a particular 
formulary or institute a price structure for the reimbursement of covered Part D drugs.”63  By not 
giving Medicare, one of the largest global purchasers of pharmaceuticals, the right to negotiate 
prices, the average per capita costs within the Part D prescription drug program have risen and are 
                                                 
58 David Belk and Paul Belk, supra note 54. 
59 Id. 
60 Zachary Brennan, European Drug Prices: New Commission Report on What Policies Work and What Could 
Work, REGULATORY AFFAIRS PROFESSIONALS SOCIETY (Feb. 25, 2016), https://www.raps.org/regulatory-
focus%E2%84%A2/news-articles/2016/2/european-drug-prices-new-commission-report-on-what-policies-work-
and-what-could-work. 
61 Id.  
62 Robert Langreth, Drug Prices, BLOOMBERG, May 11, 2018, https://www.bloomberg.com/quicktake/drug-prices. 
63 42 U.S.C. 1395w-111(i)(1) (2017). 
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projected to  rise 4.7% annually over the next decade. 64  
The length of patent and exclusivity protections, the various commercial approaches taken 
by the drug companies and the government’s own imposed restraints to limit drug prices have, 
collectively and individually, added to the size and scope of this national crisis.  A crisis that 
impacts individuals, companies and government budgets.   
IV. Parties to the Price Increases 
Drug prices impact a variety of parties.  Individuals, employers, and the government are 
harmed from the increasing prices in their own ways.  Meanwhile, pharmaceutical and insurance 
companies derive an economic benefit from the increasing costs.   
Individuals are the greatest impacted from increased pharmaceutical costs.  A 2009 study 
conducted by Elizabeth Warren found that 62.1% of all bankruptcies were due to medical bills.65  
Moreover, the high cost of prescriptions are causing more and more patients to not fill or not 
complete their course of treatment according to the Center for Disease Control and Prevention 
(“CDC”).66  Skipping medications is known to worsen an individual’s health and quality of life, 
resulting in higher medical costs.  A study from the Annals of Internal Medicine found that a lack 
of adherence to self-administered medications causes approximately 125,000 deaths in the United 
                                                 
64 Juliette Cubanski, Tricia Neuman, Searching for Savings in Medicare Drug Price Negotiations, KAISER FAMILY 
FOUNDATION (Apr. 26, 2018), https://www.kff.org/medicare/issue-brief/searching-for-savings-in-medicare-drug-
price-negotiations/ (From 2007 through 2013, the average per capita costs increased 2.4%, and increased 4.4% 
between 2013 and 2016). 
65 Kimberly Amadeo, Medical Bankruptcy and the Economy, THE BALANCE (May 16, 2018), 
https://www.thebalance.com/medical-bankruptcy-statistics-4154729. 
66 CENTERS FOR DISEASE CONTROL AND PREVENTION, STRATEGIES USED BY ADULTS TO REDUCE THEIR 
PRESCRIPTION DRUG COSTS (2015) (The study states that 8% of adults in general do not take their medication to save 
money.   Additionally, the study notes that adults between 18 and 65 were twice as likely as those over 65 to not 
take their medication.  Moreover, 14% of uninsured adults, 10% of Medicaid patients and 6% of privately insured 
patients do not take their medication to save money.)   
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States67 and costs the U.S. health care system between $100 billion and $289 billion annually.68   
Increased pharmaceutical costs also directly impacts employers.  Under the Affordable 
Care Act (“ACA”), employers are required to provide health insurance to full-time employees.  
The increase in spending for pharmaceuticals has been a primary reason for annual increases of 
employer health care costs.69  Retail drugs consist of approximately 21% of employer insurance 
benefits.70  A 2017 survey by Mercer, a consultancy firm, found that 46% of employers would take 
steps to cut costs through new strategies such as high-deductible health plans, which shift the 
burden of initial medical costs to patients, but have lower monthly premiums.71 
 Pharmaceutical costs negatively impact the government as well.  In 2017, the National 
Health Expenditure, the official measurement of total healthcare spending, accounted for 17.9% 
of the U.S.’s GDP.72   Medicare spending was 15% of the total federal budget in 2017 and is 
projected to rise to 18 percent by 2028.73  Medicare benefit payments totaled $705.9 billion.74  
Medicaid, ACA, and Children’s Health Insurance Program spending was 11% of the federal 
budget in 2017.  Combined, Medicare and Medicaid spend $174 billion on prescription 
medications in 2016.75 
                                                 
67 Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al., Interventions to Improve 
Adherence to Self-administered Medications for Chronic Diseases in the United States: A Systematic Review, 157 
Annals of Internal Med.785–95 (2012). 
68 Id. 
69 Robert Galvin, Troyen Brennan, Can Employers Take a Bigger Role in Controlling Drug Costs, HEALTHAFFAIRS, 
(Feb. 17, 2017), https://www.healthaffairs.org/do/10.1377/hblog20170217.058822/full/. 
70 Rabah Kamal, Cynthia Cox, What are the recent and forecasted trends in prescription drug spending?, 
PETERSON-KAISER HEALTH SYSTEM TRACKER (December 20, 2017), https://www.healthsystemtracker.org/chart-
collection/recent-forecasted-trends-prescription-drug-spending/?_sf_s=recent+trends#item-start. 
71 Divya Grover, Costly drugs to weigh on U.S. employers’ expenses in 2018: survey, REUTERS (Sept. 18, 2017), 
https://www.reuters.com/article/us-usa-healthcare-survey/costly-drugs-to-weigh-on-u-s-employers-expenses-in-
2018-survey-idUSKCN1BT1FR. 
72 CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURES 2017 HIGHLIGHTS 1 (2018). 
73 Juliette Cubanski, Tricia Neuman, The Facts on Medicare Spending and Financing, KAISER FAMILY FOUNDATION 
(June 22, 2018), https://www.kff.org/medicare/issue-brief/the-facts-on-medicare-spending-and-financing/. 
74 CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH EXPENDITURES 2017 HIGHLIGHTS 2 (2018). 
75 Tami Luhby, Check out how much Medicare spends on drugs, CNN BUSINESS (May 15, 2018), 
https://money.cnn.com/2018/05/15/news/economy/medicare-drug-spending/index.html. 
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Insurance companies are also directly impacted and must manage drug prices. Increased 
drug prices lead to increased costs of insurance.  However, rather than bearing the costs 
themselves, insurance companies transfer the costs onto purchasers in the form of increased plan 
prices or higher co-pays.76 
With the demand for more cost control, pharmaceutical companies argue that drug prices 
are high in order to bankroll development of future medical advances, that pharmaceutical 
advances justify price, and restricting prices would harm innovation.  Studies show the average 
cost of developing a prescription drug which gains market approval is $2.6 billion.77  Much of their 
defense is undermined by their own success.  Estimated pharmaceutical and biotechnology sales 
revenue increased from $534 billion to $775 billion from 2006 through 2015 with approximately 
67% of all drug companies increasing profit margins during the same time.78  Interestingly, the 
twenty-five largest pharmaceutical companies, had an average profit margin between 15 and 20% 
compared an average profit margin for nondrug companies for the larges 500 globally of 4 to 9%.79   
Additional facts further weaken that drug companies’ arguments.  First,  more than 50% of 
important discoveries and 85% of basic discoveries are made in independent academic centers.80 
Second, a study from the Journal of Clinical Oncology found that drug effectiveness does not 
necessarily translate to cost effectiveness for cancer drug pricing.81  Third, the median deal of 
                                                 
76 ELSEVIER CLINICAL SOL., THE IMPACT OF RISING GENERIC DRUG PRICES ON THE U.S. DRUG SUPPLY CHAIN 1 
(2015).   
77 Rick Mullin, Tufts Study Finds Big Rise in Cost of Drug Development, C&EN (Nov. 20, 2014), 
https://cen.acs.org/articles/92/web/2014/11/Tufts-Study-Finds-Big-Rise.html. 
78 UNITED STATES GOVERNMENT ACCOUNTABILITY OFFICE, DRUG INDUSTRY: PROFITS, RESEARCH AND 
DEVELOPMENT SPENDING, AND MERGER AND ACQUISITION DEALS 1 (2017). 
79 Id.  
80 Hagop Kantarjian and Vivian Ho, Opinion, The Harm of High Drug Prices, U.S. NEWS (Dec. 12, 2016), 
https://www.usnews.com/opinion/policy-dose/articles/2016-12-12/the-harm-of-high-drug-prices-to-americans-a-
continuing-saga. 
81 Bruce E. Hillner, Thomas J. Smith, Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study 
in the Challenges Associated With 21st-Century Cancer Drug Pricing, 27 J. of Clinical Oncology 2111-13 (2009). 
http://ascopubs.org/doi/pdf/10.1200/JCO.2008.21.0534 
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mergers and acquisitions increased while the volume remained steady, suggesting that 
manufacturers are buying drug discoveries and not developing them in-house.82  Fourth, research 
and development equaled 17% of their revenue for the thirteen largest drug companies from 2011 
through 2017.83  While the pharmaceutical companies’ arguments must be taken into account, they 
must also be scrutinized carefully.  
Any remedial action must take into consideration all parties so that advances in medications 
can continue while allowing individuals to benefit from those innovations without damaging the 
economic health of individual, employers and governments.     
V. Steps being taken—State Governments 
Since 2015, states have enacted a wide variety of policy initiatives related to prescription 
drug regulation, with more than 200 signed bills from forty-five states to affect pricing, payment, 
and costs of prescription drugs.84    In 2018 alone, forty-one states enacted 121 bills regulating the 
pharmaceutical industry.85  Legislation has been adopted by both Republican and Democrat 
leaning states to signal  bipartisan concern over this growing public health concern.  State measures 
include: (1) Drug cost transparency; (2) allowing for importation of prescription drugs from 
Canada; (3) drug anti-price gouging; (4) drug co-payment limitations; and (5) determining 
Medicaid prescription coverage based upon negotiation and cost effectiveness.86  Some measures 
have been rejected by the courts as being unconstitutional.   
First, more than 60 drug cost transparency bills have been proposed in thirty states across 
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the country.87  Among these 60 bills, twenty-seven have been implemented in seventeen states, 
and many more are still pending.88  Most notably, California and Vermont are considered 
“pioneers” of drug transparency having been the first states to implement such plans.  These bills, 
which apply to both brand-name and generic drugs, are designed to identify the costs that 
contribute to drug manufacturer expenses, list prices, and unveil the business practices of PBMs.89  
PBMs are heavily scrutinized due to the secrecy of their business practices. 
Generally, transparency bills require drug manufacturers to report the reasons behind drug 
price increases that exceed 10% or more over a twelve-month period.90  The price increase 
rationale must be in an understandable and appropriate format and are publicized.  The 
transparency “give[s] hospitals access to pricing information that they could use when 
communicating with manufacturers to establish rates.”91  Some believe drug price transparency 
would hold manufacturers accountable for the cost of medications.92  Depending upon the specific 
state’s requirements, failure to comply with the reporting requirements may result in fines up to 
$10,000 per day.93  States with drug cost transparency laws often stipulate differing reporting 
requirements.  California, for example, places requirements on both pharmaceutical manufacturers 
and  health insurers.94  Manufacturers must provide purchasers with 60-day advance notification 
of price increases “that exceeds a specified threshold” for prescription drugs currently on the 
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market, including reasons and justifications for such increases.95  Manufacturers must also provide 
justification of launch prices for new drugs.96  Health insurers filing rate information must report 
specific cost information regarding prescription drugs covered under their plan, including generic, 
brand-name, and specialty drugs and the percentage of their insurance premium that are 
attributable to prescription drugs.97  Nevada, in addition to price increase reporting justifications, 
requires the (i) reporting of free goods or compensation by sales representatives to licensed health 
providers and (ii) the dollar value of manufacturer drug rebates they collect.98     
Second, states have taken steps to increase competition through the importation of drugs.  
In May 2018, Vermont enacted legislation that enabled the wholesale importation of prescription 
drugs into Vermont from Canada.99  Since then, Colorado, Louisiana, Montana, New York, 
Oklahoma, West Virginia, and Wyoming have introduced similar bills.100  These bills apply a 
market-based approach to decreasing pharmaceutical prices by “providing more affordable 
medicines from Canada, where prescription drugs cost on average 30 percent less than in the 
United States.”101  The approach would create a state-administered system of wholesale 
importation and distribution, limited solely to pharmaceuticals from Canada and by contracting 
with a fully licensed, regulated Canadian supplier that is compliant with Canadian law.102  The 
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Canadian supplier would manage distribution to state-licensed pharmacies.  Participating states 
would decide the extent of coverage for public and private health plans and programs. 
However, the state importation legislation requires federal approval, thereby delaying the 
legislation’s implementation.  Section 804 of the Medicare Prescription Drug, Improvement, and 
Modernization Act of 2003 (“Section 804”) provides that the Health and Human Services 
Secretary (“HHS Secretary”) may allow the importation of prescription drugs from Canada if it 
can be proven that it will (1) pose no additional risk to the public’s health and safety and (2) result 
in a significant reduction in the cost of covered products to the American consumer.103  Proponents 
argue that importation would be safe and produce savings for American consumers.  Specifically, 
Section 804 would be satisfied because: (i) a state must select a Canadian supplier that is licensed 
and regulated under Canadian law and could be licensed under state pharmacy or wholesaler law 
as well; (ii) a state would select drugs that are approved for the Canadian market; (iii) participants 
would agree to purchase and reimburse drugs at the import price and patient cost sharing would 
be based upon the import price as well; (iv) states must monitor and audit the system for 
compliance, safety, and savings; and (v)  the legislation (a) allows for greater transparency for 
consumers and (b) requires the imported products be distributed in-state only.   
HHS does not seem t convinced of the legislation’s merits.104  However, there has yet to 
be a HHS Secretary that has deemed Section 804’s standard to be satisfied.  Alex Azar, the current 
HHS Secretary, stated in May 2018 that programs designed to reduce pharmaceutical prices 
through importation are “just a gimmick.”105  In dissent of importation programs, Azar referenced 
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a 2004 analysis by the Congressional Budget Office (“CBO”) that determined that importation 
would not have a meaningful impact on U.S. prescription drug prices.106  Azar, relying upon 
findings from four prior FDA commissioners, also stated that allowing drugs to come into the U.S. 
from Canada raises safety concerns.107  Regardless of the potential benefits, importation from 
Canada will not occur until approval by the HHS Secretary.   
Another unique approach to tackle the rise in drug prices is the implementation of anti-
price gouging laws.  In October of 2017, Maryland became the first state to implement such a law, 
which prohibited a manufacturer or wholesale distributor from engaging in “price gouging” in the 
sale of an essential off-patent or generic drug.108  The act defined price gouging as “an 
unconscionable increase in the price of a prescription drug.”109  An “unconscionable increase” was 
further defined as an increase that “is excessive and not justified by the cost of producing the drug 
or the cost of appropriate expansion of access to promote public health.”110  A manufacturer or 
wholesale distributor determined to be in violation of the act faced numerous legal consequences, 
including a civil penalty of $10,000 per violation or an action enjoining the sale of the medication 
at the increased price.111  Ultimately, the act was challenged and struck down by the Fourth Circuit 
Court of Appeals in April of 2018.112  The Court held that the act violated the Dormant Commerce 
Clause because it directly regulated the price of transactions that occurred outside the state of 
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Maryland.113 As such, the act imposed a significant burden on interstate commerce involving 
prescription drugs.114  Since being struck down, similar bills in 16 other states have stalled, with 
bills in 11 states no longer active.115     
Fourth, legislation addressing cost-sharing and deductibles has been adopted in 20 states 
across the country.116  This legislation implements caps on pharmaceutical pricing without directly 
regulating the prices themselves, focusing primarily on specialty drugs that are typically more 
expensive for consumers.  In California, “cap the copay” legislation was enacted.117  This law 
prohibits an individual health insurance policy or group health care service plan that provides 
coverage for anticancer medications from requiring an enrollee to pay more than $250 in 
copayments and coinsurance for a 30-day supply of an individual prescription.118  Alongside 
California, 19 other states have adopted similar cost-sharing legislation.119  In January of 2018, the 
Biotechnology Innovation Organization commissioned a report seeking to understand the 
economic impact of prescription drug cost-sharing cap legislation.  The report found that, 
compared to states without cost-sharing cap legislation, California could expect approximately a 
one percent decrease in spending for individual plans and a three percent decrease for group 
plans.120  However, the net paid costs would remain unchanged as insurers compensated for the 
copayment and coinsurance cap by increasing premiums accordingly.  Thus, any benefit may be 
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substantially limited.   
Fifth, a majority of states have implemented legislation, subject to CMS approval, that 
determines Medicaid prescription drug coverage based upon negotiation and cost-effectiveness.121  
Under this legislation, states have adopted four payment models for determining cost-
effectiveness: (1) establishing a Medicaid drug cap; (2) utilizing value-based contracting; (3) a 
subscription-based payment model; and (4) a closed formulary approach.  In 2017, New York 
established a Medicaid drug cap to balance the growth of drug expenditures with the growth of 
total Medicaid expenditures.122  Under New York’s law, New York’s Drug Utilization Review 
Board follows a recommended target for the value of a Medicaid rebate to be paid by the 
manufacturer to the State.123  If a satisfactory rebate agreement is not agreed upon, any non-
cooperating manufacturers are required to file a detailed financial report including, but not limited 
to, the actual cost of developing, manufacturing, producing and distributing the drug; research and 
development costs; administrative and marketing costs; the price of the drug when sold outside the 
United States; the average rebates and discounts provided per payer type in the state; and the 
average profit margin of each drug.124   
In 2018, CMS approved Oklahoma legislation that utilized a value-based model.  The 
value-based model authorizes the state to negotiate supplemental rebate agreements for 
pharmaceuticals involving value-based purchasing agreements with manufacturers that could 
produce additional rebates for states if specific outcomes were not achieved.125  Thus, if certain 
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clinical or cost benchmarks were not achieved, the drug manufacturer is required to provide 
additional rebates to the state.126  Louisiana adopted a subscription-based payment model for 
Hepatitis C drugs.127  Under this model, the state pays drug manufacturers for unlimited access to 
the treatment for individuals enrolled in Louisiana’s Medicaid or correctional system.128  The cost 
would be equal to or less than the state’s current expenditures for providing the medication to these 
groups.129  Lastly, Massachusetts adopted a closed formulary approach.  Under this approach, the 
state would be not be required to cover every drug made by a manufacturer that participates in the 
federal Medicaid rebate program.130  Instead, the law would have allowed the state to choose which 
prescription drugs to cover according to cost effectiveness and their beneficiaries’ needs.131  
However, CMS denied the Massachusetts law because the proposal would have also preserved 
statutory rebates.132  CMS stated that they would consider a closed-formulary approach in 
Medicaid if the state agreed to forgo the available mandatory rebates through the Medicaid rebate 
program.133 
State legislative efforts have had mixed success.  Some of the legislation has been effective 
in curtailing increases in pharmaceutical costs, while the benefits of other legislation have been 
blocked by the courts or a reluctant federal government.    
VI. Steps being taken—Federal Government 
Alongside state legislation, the federal government has taken unilateral steps to curtail the 
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rising costs of pharmaceuticals.  In May of 2018, President Donald Trump’s administration 
released the American Patients First blueprint to explain initiatives designed to lower drug prices 
and reduce out-of-pocket costs for consumers.134  The blueprint’s initiatives are premised upon 
increasing competition, improving negotiation, creating incentives to lower list prices, and 
reducing patient out-of-pocket spending costs.135   
Pursuant to its Drug Competition Action Plan, the FDA implemented two new policies in 
2017 to increase competition in the pharmaceutical industry.  First, the agency published a list of 
off-patent, off-exclusivity, branded drugs without approved generics in order to improve 
transparency and encourage the development and submission of new generic drug applications for 
drugs with limited competition.136  Second, the agency implemented a new policy to expedite the 
review of generic drug applications in situations where competition is limited.137  FDA 
Commissioner Scott Gottlieb stated, “[g]etting safe and effective generic products to market in an 
efficient way, being risk-based in our own work and making sure our rules aren’t used to create 
new obstacles to new competition can all help make sure that patients have access to more lower-
cost options.”138  In 2017 alone, over 1,000 generic drugs were approved and saved American 
consumers and taxpayers approximately nine billion dollars.139      
In May, Congress passed, nearly unanimously, both the Know the Lowest Price Act and 
the Patient Right to Know Drug Prices Act.140  These laws ban the inclusion of pharmacy “gag 
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clauses.”141  This federal action follows after twenty-nine states enacted laws to protect pharmacies 
and pharmacists from penalties by a PBM for disclosing such information.142  The CBO estimates 
the law will reduce the deficit by $40 million over the next decade.143   
The Trump administration plans to further increase competition in 2019 by limiting 
companies from using its 180-day exclusivity period to indefinitely delay real competition and 
savings for consumers.144  The concern stems from first filers that receive tentative generic drug 
approval, but then intentionally delay seeking final approval as a means to block competitions.145  
Thus, first filers “park their exclusivity, and consumers are denied access to generic products and 
must keep paying brand price.”146  In its 2019 budget proposal, HHS proposed legislation that 
proposal “makes the tentative approval of a subsequent generic drug applicant that is blocked 
solely by a first applicant’s 180-day exclusivity, where the first applicant has not yet received final 
approval, a trigger of the first applicant’s 180-day exclusivity.”147  HHS believes that this proposal 
will enhance competition and expedite timely access to generic drugs without compromising the 
safety of the drug approval process.  The proposal is estimated to create $1.8 billion in Medicare 
savings over the next decade.148 
 
The federal government is also implementing measures to improve negotiation, especially 
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in regard to Medicare.  While the blueprint does not go so far as currently allowing Medicare to 
directly negotiate prices with manufacturers, it does propose to alter regulations under Part C and 
Part D of the Medicare Prescription Drug Program to allow for faster mid-year substitutes.149  Mid-
year substitutions permit Part D sponsors to immediately substitute generics for brand-name drugs 
on the same or lower cost-sharing tier.150  Currently, Medicare participants face difficulties when 
trying to substitute prescription drugs.  Removing limitations on mid-year substitutes promotes the 
use of generic drugs while decreasing the cost imposed on Medicare participants.   
Outside of Medicare negotiations, the federal government plans to work alongside the 
Department of Commerce, the U.S. Trade Representative, and the U.S. Intellectual Property 
Enforcement Coordinator to address the disparity between drug prices in the U.S. compared to 
other developed countries.151  However, no specific plans have been created or implemented.  
The federal government also seeks to establish a maximum for out-of-pocket spending to 
benefit those that spend the most on drugs.152  The plan suggests an “inflation penalty” in the form 
of increased rebates from drug companies whose price increases are greater than the rate of 
inflation.153  These changes would create strong incentives for manufacturers to negotiate lower 
prices on over-priced drugs.  The government also plans to combat the high list prices through 
increased transparency; specifically, the FDA has sought to include list prices in direct-to-
consumer (“DTC”) advertising.154  CMS has sought to hold manufacturers “accountable for high 
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price increases, highlight drugs that have not taken price increases, and recognize when 
competition is working with an updated drug pricing dashboard.”155  Critics contend that there is 
no evidence that inclusion of list prices in DTC advertising will reduce pharmaceutical prices.  
Instead, they argue that focus on price disclosure “is a distraction from additional action that would 
benefit people—lowering prices.”156  Industry supporters believe that the measure will confuse, 
mislead, and potentially harm patients.  Jon Bigelo, an executive director of the Coalition for 
Healthcare Communications wrote that it may, “discourag[e] them from initiating important 
conversations with health providers and seeking medical care they need.”157 
The federal government is also seeking to reduce out-of-pocket costs by implementing a 
policy in which biosimilar drugs receive similar billing and payment codes under Medicare Part 
B.158  Biosimilar drugs are FDA-approved, which are determined to have a biological or chemical 
structure that is interchangeable with an FDA-approved biological product.159  The FDA 
implemented the biosimilar process “as a way to provide more treatment options, increase access 
to lifesaving medications, and potentially lower health care costs through competition.”160  It is 
anticipated that this program will incentivize the development of additional lower-cost biosimilars 
at a cheaper production cost while maintaining innovation among the pharmaceutical 
manufacturers.161 
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Lastly, the government has sought to reform the 340B Drug Discount Program.  The 340B 
program allows for qualified medical providers to purchase outpatient drugs at deep discounts.162  
Because the program does not require these discounts to be passed onto patients or payers, the 
program promotes financial stability by allowing participating providers to generate revenue from 
the sale of these drugs.163  Effectively, the program allows these entities to “stretch scarce financial 
resources as far as possible.”164  However, there are concerns that a lack of program oversight has 
harmed the program.165  A 2016 review by the Office of Pharmacy Affairs in the Health Resources 
and Services Administration (HRSA) found that HRSA audited less than two percent of all 
participating providers.166  There are also concerns as to whether new participants are using the 
340B benefits to improve healthcare access for low income patients or whether the 340B revenue 
is used to increase revenue for hospital systems.167  Under the current statute, DSHs do not have 
to demonstrate that the 340B revenues are utilized to enhance safety-net engagement.168  Rather, 
they must only demonstrate that they provide a “sufficient amount” of inpatient services to 
Medicaid and low-income Medicare beneficiaries.169  The Office of the Inspector General in 2014 
found that most DSH hospitals did not offer discounted prices to uninsured patients.170 
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As a result, the 340B PAUSE Act and the 340B HELP Act have been proposed.171  The 
two acts, taking slightly different approaches, propose a two year freeze on the approval of new 
disproportionate share hospitals (DSHs), their clinics, and contract pharmacies.172  The two Acts 
also propose increasing reporting requirements and enforcing eligibility criteria for DSHs and their 
affiliates and imposing additional requirements for pharmacies.173  The enactment of this 
legislation aims to increase accountability for those participating under the 340B program and 
increase care for underprivileged patients by assuring that they receive the discounted prices as 
provided under the current 340B program.  Critics of the PAUSE Act and HELP Act contend that 
there are issues regarding the scope and implementation.  Critics also argue that freezing the 
approval of additional DSHs would limit the accessibility for those that the 340B program seeks 
to protect.   
Since the Trump administration released its blueprint to reduce prescription drug prices 
and out-of-pocket costs earlier this year, notable changes to the pharmaceutical sector have 
occurred.  Within the first 100 days, fifteen drug companies reduced their priced and either rolled 
back planned price increases or committed to price freezes for the rest of 2018.174  During this 
period, there was 60% fewer brand-drug price increases than during the same period in 2017.175  
Price decreases occurred in 54% of generic and brand-name drugs than during the same period in 
2017.176  Dan Best, Senior Advisor to the Secretary for Drug Pricing Reform, referred to the 
rollbacks as “unprecedented recognition of fundamental changes going on in drug markets.”177  
Additionally, the FDA in July of 2018 approved more generic drugs than in any other month in its 
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history.  These approvals included a generic version of the EpiPen and a biosimilar competitor for 
a costly drug which fights infections in cancer patients.178 
While these facts are an encouraging sign that the drug companies are reacting positively 
to the increased scrutiny, many critics contest that the pharmaceutical industry improvements are 
not correlated to the Trump administration’s blueprint.  Health policy expert Rachel Sachs, an 
associate professor of law at Washington University in St. Louis, opined that, “[t]he administration 
seems to be feeling a need to deliver results quickly on the drug pricing front, and so they are 
pointing to metrics like fewer price increases…rather than metrics that will be meaningful to 
patients.”179  Additionally, HHS’s analysis was limited in its access to information and relied 
instead upon a subscription database, AnalySource, which was unable to link directly to sales 
volume.180  HHS acknowledged flaws in its analysis stating that its calculation was limited to 
“simple counts and descriptives” of price increases.181  Because HHS lacked supporting 
information and could not identify the magnitude of the price changes, HHS could not determine 
the blueprint’s effectiveness on overall drug spending.182   
Overall, the federal government has implemented a vast number of policies with the goal 
of reducing the rising costs of pharmaceuticals.  While some policies have seen immediate results, 
others have not.  Regardless of the determination of success, a reduction in pharmaceutical prices 
is more likely to occur through increased federal legislation. 
VII. Proposed Strategies for Combatting the Increasing Costs 
Various market, legislative, and societal approaches have been taken, with mixed results 
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to impact the cost of pharmaceutical drugs.  In evaluating the various approaches to combating the 
rise in pharmaceutical prices, three measures provide the greatest upside: (1) allowing international 
importation of approved drugs from Canada; (2) allowing direct negotiation for Medicare; and (3) 
expediting approval of generic drugs.    
A. Allowing importation of drugs from Canada 
Allowing the importation of drugs from Canada will have the greatest impact on reducing 
the cost of pharmaceuticals.  Despite the apprehensions over the importation of pharmaceuticals 
from Canada, importation legislation (1) does not pose any additional risk to the public’s health 
and safety; and (2) would result in a significant reduction in the costs of covered products to the 
American consumer.  
Steep regulatory requirements embedded in the legislation would ensure that imported 
drugs will not pose an additional risk to the public’s health and safety.  Under the various 
legislation, the importer must be licensed in accordance with Canada’s laws and state specific 
pharmacy and wholesaler regulations.  Imported drugs must be approved by the Canadian 
regulatory board, Health Canada; an agency that the FDA previously recognized and with whom 
the parties agreed to cooperate on regulatory requirement and standards.183  Finally, the imported 
drugs would only be distributed in-state, preventing interstate transportation and limiting possible 
contamination.   
Enacting this program will also result in a significant savings given the material difference 
in drug prices between Canada and the U.S.  According to Vermont Senator Bernie Sanders, drug 
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importation could save tax payers 6.8 billion dollars over ten years.184  While HHS disagrees with 
Senator Sanders’ economic analysis, arguing that drug importation from Canada alone was 
projected to produce only a negligible reduction in drug spending it is hard to argue that any 
competition would not result in savings for American patients. 185  Furthermore, HHS continues to 
rely on a 2004 Congressional Budget Office  (“CBO”) study that would seemingly be outdated 
given the significant developments in drug manufacturing, legislation and markets.  As such, any 
delay in implementing drug importation should be based on a new study to better understand the 
economic benefits of such legislation.     
B. Allowing Medicare to directly negotiate with pharmaceutical companies 
Amending the Social Security Act, so that Medicare may negotiation with drug 
manufacturers, pharmacies and PDP sponsors, and allow particular formulary or institute a price 
structure for the reimbursement of covered Part D drugs would be a seismic step in combating 
unbridled increases drug prices.  The Center for Economic and Policy Research estimated federal 
savings between $230 billion to $541 billion over ten years if Medicare negotiated the same prices 
for drugs as countries where prices are set automatically.186  The analysis also estimated annual 
savings of approximately fifteen billion dollars per years if Medicare paid the same prices as 
Medicaid and the Veterans Association.187  Such an amendment has broad bipartisan support.  
Furthermore, implementation would be widely supported by the American people.  According to 
the Henry J. Kaiser Family Foundation, among the public, Medicare negotiation is supported by 
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96 percent of Democrats, 92 percent of Republicans and 92 percent of Independents.188 
The impediment to such legislation appears to be the CBO 2004 study, and its analysis that 
giving the HHS Secretary such authority would produce a “negligible effect on cost management 
efforts.”189  Its conclusion relied on the expectation that the HHS Secretary would be limited in his 
ability to negotiate substantial discounts.  Instead, the Congressional Budget Office proposed that 
savings could be achieved by authorizing the HHS Secretary to set drug prices administratively 
rather than negotiating on prices.190  The Congressional Budget Office’s conclusion on savings 
does not incorporate its propositions into its calculation.   
 Given the size and scope of the Medicaid budget and the minimal leverage that such a 
consumer would have at any negotiating table, it is difficult to understand CBO’s conclusion that 
HHS could not seek significant reductions in drug pricing.   Even more compelling would be the 
leverage that Medicare and the Veteran’s Association would add to any such negotiations.  
Government, as a major purchaser of pharmaceuticals, should not be hampered in price 
negotiations as any decreases, even negligible, in drug pricing would undoubtedly have significant 
impacts on federal and state budgets.   
C. Expediting approval of generic drugs 
Expediting approval of generic drugs will aid in reducing pharmaceutical costs by 
increasing competition in the open market.  Manufacturers enjoy a lengthy period of non-
competition from with a patent, during which time they can charge a suitable, albeit not necessarily 
reasonable, price to reward their innovation.  But this monopoly period should not be enhanced by 
a slow approval process for generic drugs.  The availability of generic drugs, after patent 
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expiration, demonstrably shows significant price decreases.     
Enacting HHS’s 180 day acceleration rule proposed in their 2019 budget, the first filers 
would be encouraged to move their applications without delay; thereby getting generic drugs to 
market faster.  Furthermore, abbreviating the applications but not testing would further accelerate 
the influx of generic drugs into the market.  According to the FDA’s policy manual, applications 
for generic products may receive expedited review if there are no blocking patents or exclusivities 
and if the reference drug as less than three approved generics.191  Helping generic drugs into the 
market quickly and safely will have the tremendous effect of decreasing drug prices.     
VIII. Conclusion   
Increased pharmaceutical costs have posed an ever-growing public health problem for the 
nearly thirty years.  These increases, well above the rate of inflation, have compromised some 
individual’s health as they elect to forego treatment due to cost; causing long-term health 
implications; and imposing costs upon the public health system.  Understandably, pharmaceutical 
companies need to be able to recoup investments in drug research and deliver returns for their 
shareholders in order to continue to deliver innovative drugs.  However, without effective 
mechanisms to limit increases in drug costs drug prices are causing a public health care crisis. 
Drug prices are causing economic and physical harm to the Americans.  As drug prices rise 
without restraint, individuals, employers and federal and state governments must find ways to 
cover these costs from strained resources.  Moreover, studies show that patients skip taking some, 
if not all, their prescribed medication because of drug prices, which in turn leads to additional 
health problems, loss productivity and, in some cases, death.  These cost add further burden on 
society and can be measured in the billions.    
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Federal and state governments have taken different approaches to limit drug increases and 
their effect, from transparency regulations, use of generic drugs, payment restrictions and even 
public humiliation. Some of these measures have worked, others moderately so, and still others 
are obstructed by a lack of interest or belief that a particular legislation would be more than 
negligibly helpful.     
But given the change and, if fully embraced, by the purchasing factions, some measures 
can significantly combat the rise in drug prices.  Allowing greater competition by importing 
medications from abroad, specifically Canada, would reduce drug prices.  Further expediting the 
approval and release of generic drugs into the market would force brand-name drugs to reduce 
prices or risk significant loss in a drug’s market power.   But the most significant change would be 
to unleash the power of the federal government, not to impose regulations, but to use market power 
to demand cost adjustments and limit price increases on drugs.   Each of these measures on its own 
would have significant, if not material, benefit to patients and providers.   But taken together, these 
three approaches would provide patients safe and affordable medications and the drug market to 
operate in a more natural commercial market without the unnecessary restraints imposed on 
providers and payers.   
